Yesterday | Seeking Alpha
King Pharma Income Statement Analysis for September 2009 Quarter
King Pharmaceuticals, Inc. earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year.
ZymoGenetics says restraining orders lifted
Puget Sound Business Journal ZymoGenetics Inc. said Friday that a federal judge in Tennessee has removed three temporary restraining orders imposed on the company over marketing and promotion of its lead drug, Recothrom.
King Pharmaceuticals to Present at Credit Suisse Healthcare Conference
King Pharmaceuticals, Inc. today announced plans to provide a live webcast of its presentation scheduled for Thursday, November 12, 2009, at 9:00 am Mountain Standard Time , at the Credit Suisse 2009 Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona.
King Pharmaceuticals, Inc. reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents.
Two years after Mylan Inc. completed a $6.8 billion deal for Merck KGaA's worldwide generic drug business, CEO Robert J. Coury is looking for deals to acquire makers of brand-name drugs.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
FDA Issues Complete Response Letter For CorVuea
Main Category: Cardiovascular / Cardiology Also Included In: Regulatory Affairs / Drug Approvals King Pharmaceuticals, Inc.
FDA Sends Warning Letter to King Pharmaceuticals Over Embeda Videos
ROCKVILLE, Md., Oct. 21, 2009--The Food and Drug Administration today posted on its website a warning letter send to King Pharmaceuticals over two Embeda video news releases.
SADIF Analytics releases new summary due diligence report for Perrigo Company
Ilhavo, Portugal a ' 09/10/2009 a ' SADIF Investment Analytics, announces a new summary due diligence report covering Perrigo Company .
RothmanResearch.com Stock Review for AEM, CS, KG, LSI, DYN and MDR
On this day, we have begun tracking the following companies as they have shown remarkable correction in recent days, you can access these free reports with a number of other reviews by signing up for your complimentary membership at : http://www.rothmanresearch.com/ Companies been researched today are: Agnico-Eagle Mines Ltd.
WallStSense.com Fundamental & Technical Coverage of ATI, ECA, GGB, DNE, KG and HTE
Our analysts have issued free ratings reports on the following six companies: Allegheny Technologies Inc.
Public relations, press release distribution, investor relations, SEC filing
BRISTOL, Tenn.-- --King Pharmaceuticals, Inc. today announced plans to provide a live webcast of its presentation scheduled for Tuesday, September 22, 2009, at 11:00 a.m. ET, a... 09/17/2009 - 10:20 AM MMC Declares Quarterly Dividend NEW YORK-- --The Board of Directors of Marsh & McLennan Companies, Inc.
King Pharmaceuticals to Present at UBS Global Life Sciences Conference
King Pharmaceuticals, Inc. today announced plans to provide a live webcast of its presentation scheduled for Tuesday, September 22, 2009, at 11:00 a.m. ET, at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York, New York.
AgraQuest Partners With Alpharma to Bring New Technology to Animal...
DAVIS, CA and BRIDGEWATER, NJ -- -- 09/11/09 -- AgraQuest Inc. and Alpharma Animal Health announced today that they have agreed to terms for a supply agreement in which AgraQuest will supply their proprietary strain of Bacillus subtilis.
Public relations, press release distribution, investor relations, SEC filing
Paula A Cox announced today that Bermuda has been elected Vice Chair of the Steering Group of the new Global Forum at t... LOS ANGELES-- --The Fire Family Foundation announced today that funds are being made available to assist the victims of the fires.
Acura Pharmaceuticals and King Pharmaceuticals Provide Update on Acurox NDA
Acura Pharmaceuticals and King Pharmaceuticals Provide Update on Acurox NDA PALATINE, Ill.
DURECT Signs Long Term Excipient Supply Agreement With King...
DURECT Corporation today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY with King Pharmaceuticals, Inc.
Abuse Resistant Morphine Approved
Learn the safest practices for medication use and what to ask your doctor. One of the concerns about extended-release opioids like OxyContin is that they are easily abused.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
DURECT signs agreement with King Pharmaceuticals to supply two excipients for REMOXY
DURECT Corporation today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY with King Pharmaceuticals, Inc.
Also on Topix